Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer
Adjuvant Nab-paclitaxel Plus S-1 Versus Capecitabine Plus Oxaliplatin for Patients With Stage III Gastric Cancer After D2 Gastrectomy : a Randomised,Open-label, Phase III Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Cheng xiangdong, PhD
- Phone Number: 0571-88128041
- Email: Chengxd516@126.com
Study Contact Backup
- Name: Yu pengfei, PhD
- Phone Number: 0571-88128041
- Email: ypfzmu@163.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Recruiting
- Zhejiang Cancer Hospital;Cancer hospital of the university of chinese academy of sciences
-
Contact:
- Xiangdong Cheng, MD,PhD
- Phone Number: +86-571-88128202
- Email: Chengxd516@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age of 18-75 years;
- Histological diagnosis of stage III gastric adenocarcinoma and Gastroesophageal junction of the stomach;
- Patients are required to provide a pathologically confirmed diagnosis report and provide 4-5 histological white films obtained at baseline;;
- Patients underwent D2 radical resection within 6 weeks prior to random enrollment; and R0 resection criteria were achieved;
- Ability to perform chemotherapy within 7 days of enrollment in the randomized group;
- No prior anti-tumor treatment (including systemic chemotherapy and local radiotherapy), except for initial gastrectomy for primary lesions;
- ECOG performance status of 0-1;
- Haematological status: absolute neutrophil count(ANC) ≥1.5×109 /L, platelet count(PLT) ≥100×109 /L, hemoglobin(HB) ≥90 g/L;WBC ≥3.0×109 /L;And no bleeding tendency;
- Liver function: alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤2.5 x upper limit of normal range (ULN), alkaline phosphatase ≤2.5 x upper limit of normal range (ULN);total bilirubin (TBIL)≤1.5 x upper limit of normal range (ULN), or≤3 x upper limit of normal range (ULN) when with Gilbert's syndrome;
- kidney function: Creatinine(Cr)≤1.5 x upper limit of normal range(ULN) or Creatinine clearance >60 ml/min (calculated according to Cockroft-Gault)
- Able and willing to comply with the study plans in this protocol and sign the informed consent;
Exclusion Criteria:
- Treat with any other study drug or participate in another clinical trial with therapeutic intent within 28 days prior to enrollment;
- postoperative complications requiring clinical intervention and affecting treatment, such as stomach cramps, dumping syndrome;
- Patients known to be allergic or intolerant to clinical trial drugs;
- investigator believes will affect the subject's treatment regimen, uncontrolled serious medical diseases, including severe heart disease (such as the New York Heart Association (NYHA) Level II or more Congestive heart failure), cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure, uncontrolled infection;
- Known active infection with HIV, hepatitis B or hepatitis C;
- Other serious and uncontrolled non-malignant disease; except adequately treated cervical carcinoma in situ, non-melanoma skin Localized prostate cancer after cancer and radical surgery (PSA ≤ 10 ng/ml); no recurrence or metastasis was found based on imaging follow-up results and any disease-specific tumor markers;
- accompanied by dysphagia, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding, perforation;
- Female patients during pregnancy or lactation, who are refused to receive contraception during the childbearing age;
- The investigator judges patients who are not suitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AS
Arm A:nab paclitaxel (120mg/m2;iv;d1,8)+S-1 (<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg;po;d1-14 bid)Q3W;up to eight cycles
|
nab paclitaxel (120mg/m2;iv;d1,8)
Other Names:
S-1 (<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg;po;d1-14 bid)
Other Names:
|
|
Active Comparator: XELOX
Arm B:Capetabine(1000 mg/m2 po, d1-14 bid )+ Oxaliplatin(130mg/m2 , iv, d1)Q3W;up to eight cycles
|
Oxaliplatin(130mg/m2 , iv, d1)
Capetabine(1000 mg/m2 po, d1-14 bid )
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
3 years Diseases-free Survival rate(3 years-DFS)
Time Frame: up to 3 years
|
DFS is defined as time from the date of inclusion up to the date of disease progression or death
|
up to 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival (OS)
Time Frame: up to 3 years
|
Overall survival is defined as time from the start of treatment until death due to any reason.
|
up to 3 years
|
|
Safety as measured by number and grade of adverse events
Time Frame: up to 3 years
|
Summary adverse events according to NCI-CTCAE 5.0
|
up to 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Cheng xiangdong, PhD, Zhejiang Cancer Hospital;Cancer hospital of the university of chinese academy of sciences
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Stomach Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Capecitabine
- Oxaliplatin
- Albumin-Bound Paclitaxel
- Tegafur
Other Study ID Numbers
Other Study ID Numbers
- CSPC-KAL-GC-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.